← back to search

Diego Alignani

Navarre Institute of Health Research · ES
Area of research
Hematology · Immunology
Research interest
Research interests include Multiple Myeloma Research and Treatments, Acute Myeloid Leukemia Research, CAR-T cell therapy research, and Immune cells in cancer.
h-index
33
citations
4,101
works
221
NIH funding
primary concept
Medicine
email

Recent publications

The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes
Nature Communications 2022cited by 26position: middledoi
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development
Blood 2021cited by 26position: middledoi
Single-Cell RNA Sequencing Analysis Reveals a Crucial Role for CTHRC1 (Collagen Triple Helix Repeat Containing 1) Cardiac Fibroblasts After Myocardial Infarction
Circulation 2020cited by 260position: middledoi
Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study
Blood 2020cited by 1position: middledoi
PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas
Blood 2019cited by 97position: middledoi
Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination
Leukemia 2019cited by 65position: middledoi
Transcriptomic Profiling of Circulating Tumor Cells (CTCs) in Multiple Myeloma (MM): A New Model to Understand Disease Dissemination
Blood 2018cited by 1position: middledoi
Understanding the Cellular Origin and Pathogenic Transcriptional Programs in Multiple Myeloma (MM) and Light-Chain Amyloidosis (AL) through the Dissection of the Normal Plasma Cell (PC) Development
Blood 2018cited by 0position: middledoi
Whole-genome fingerprint of the DNA methylome during human B cell differentiation
Nature Genetics 2015cited by 339position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Elizabeth Guruceaga · Instituto de Salud Carlos III1 papers (2019–2019) · 1 papers (2019–2019) · 1 papers (2019–2019) · 1 papers (2019–2019) · 1 papers (2019–2019) · 1 papers (2019–2019) · 1 papers (2019–2019) · 1 papers (2019–2019)Juan José Lasarte · Gene Therapy Laboratory1 papers (2019–2019) · 1 papers (2019–2019) · 1 papers (2019–2019)Jon Celay · Navarre Institute of Health Research1 papers (2019–2019) · 1 papers (2019–2019)Xavier Sagaert · VIB-KU Leuven Center for Microbiology1 papers (2019–2019)Karen Bunting · New York Genome Center1 papers (2019–2019)Sandra Hervás‐Stubbs · Gene Therapy Laboratory1 papers (2019–2019)José A. Martínez-Climent · Clinica Universidad de Navarra1 papers (2019–2019)Davide Bagnara · University of Genoa1 papers (2019–2019) · 1 papers (2019–2019)Ari Melnick · Cornell University1 papers (2019–2019)